Search results
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks· 6 days agoFree Report) is one of the stocks most watched by Zacks.com visitors lately. Shares of this biopharmaceutical company have returned -15.8% over the past month versus the Zacks S&P 500 composite's ...
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoBristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024...
Bristol-Myers Squibb (NYSE:BMY) shareholders have endured a 33% loss from investing in the stock a...
Simply Wall St. via Yahoo Finance· 2 days agoIt's easy to match the overall market return by buying an index fund. When you buy individual...
Should You Pick Bristol Myers Squibb Stock At $45?
Forbes· 5 days agoDespite a Q1 beat, BMY stock corrected nearly 10% due to a lower than expected outlook for the full-year. After its recent fall, we think BMY stock has...
Investors Purchase Large Volume of Bristol-Myers Squibb Put Options (NYSE:BMY)
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Wednesday. Investors bought 69,538 put options on the company. This represents an increase of 76% compared ...
McAdam LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 4 days agoMcAdam LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities ...
Mather Group LLC. Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 5 days agoMather Group LLC. grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 7.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission ...
Bristol-Myers Squibb (NYSE:BMY) Given Average Rating of “Hold” by Analysts
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) has earned an average rating of “Hold” from the nineteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research ...
Pharma R&D productivity seen improving for the first time in years
Seeking Alpha· 2 days agoDiscover the latest findings on the return on investment from pharmaceutical...
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
NBC 10 - FOX 14 Monroe· 6 days agoBio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky ...